logo
Man dies after being pulled into an MRI by a metal chain he wore, police say

Man dies after being pulled into an MRI by a metal chain he wore, police say

Yahoo20-07-2025
A man died last week after being pulled into an MRI machine by a 'large metallic chain' police said he was wearing around his neck – highlighting the importance of checking for any metallic objects before going near the powerful magnets used in the medical imaging machines.
The 61-year-old died Thursday, a day after Nassau County police said he was pulled into the MRI machine at Nassau Open MRI in Westbury, New York, on Long Island. The victim was wearing 'a large metallic chain around his neck causing him to be drawn into the machine,' prompting an unspecified 'medical episode,' police said in a news release.
The man's entry to the room 'while the scan was in progress' was not authorized, police said.
He was taken to a hospital in critical condition before he was declared dead the following day. The investigation is ongoing, police said.
Police have not identified the victim, but CNN affiliate News 12 Long Island reported his name was Keith McAllister, according to his wife, Adrienne Jones-McAllister. She told the station she was the one undergoing the MRI.
'He went limp in my arms,' Jones-McAllister said through tears.
A person who answered the phone at Nassau Open MRI on Sunday said it had no comment.
Used often for disease detection and diagnosis, MRI stands for Magnetic Resonance Imaging, according to the National Institute of Biomedical Imaging and Bioengineering. The technology relies in part on powerful magnets to stimulate protons within a patient, who is placed inside the machine, allowing doctors to capture detailed images of the patient's anatomy.
That strong magnetic field, however, emanates beyond the MRI machine, posing a threat to those who might be wearing metallic objects or have them implanted. The magnets exert 'very powerful forces on objects of iron, some steels, and other magnetizable objects,' the scientific institute notes, with enough strength 'to fling a wheelchair across the room.'
'Turn this damn thing off!'
Jones-McAllister was getting an MRI on her knee, she told News 12, and needed help getting up afterwards. She said she asked the MRI technician to retrieve her husband for assistance.
'I yelled out Keith's name, 'Keith, Keith, come help me up,'' Jones-McAllister said. According to News 12, Jones-McAllister said her husband was wearing around his neck a 20-pound chain with a large lock he used for weight training.
'At that instant, the machine switched him around, pulled him in, and he hit the MRI,' Jones-McAllister said. She said she and the technician tried to pry her husband away from the machine.
'I'm saying, 'Could you turn off the machine? Call 911. Do something. Turn this damn thing off!''
Accident underscores risks
Because of the risks posed by an MRI machine's magnetic field, patients are urged to notify their doctors about any medical implants prior to an MRI, in case they contain any metallic materials. Pacemakers, insulin pumps and cochlear implants are all examples of implants that the NIBIB says should under no circumstances enter an MRI machine.
But items outside the machine pose risks as well, as last week's tragedy in Westbury demonstrated. Anything magnetic – from something as small as keys, to something as large (or larger) than an oxygen tank – can become a projectile, threatening the safety of anyone nearby.
'Metal in a room that has the magnet will fly across the room to the scanner, to this large magnet, and will really hit anything in its way,' Dr. Rebecca Smith-Bindman, a radiologist, told CNN in 2011.
'So within radiology training, one learns very early that that's not OK, that you can't have external metal in the room, and you can't have metal in the patient,' she said. 'That could lead to a problem.'
These accidents have happened in the past: In 2001, a 6-year-old boy was killed during an MRI at a hospital in Valhalla, New York, after a metal oxygen tank flew across the room when the machine's electromagnet turned on.
The magnetized tank struck the child, who died of blunt force trauma injuries.
These events are rare, according to the US Food and Drug Administration. Still, '(c)areful screening of people and objects entering the MR environment is critical to ensure nothing enters the magnet area that may become a projectile,' the agency says.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Aptar's First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon's Otrivin® Brand
Aptar's First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon's Otrivin® Brand

Yahoo

time20 minutes ago

  • Yahoo

Aptar's First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon's Otrivin® Brand

The Freepod® nasal spray pump, globally used with the Otrivin® brand, is now made from 52% bio-based feedstock CRYSTAL LAKE, Ill., July 29, 2025--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, is proud to announce that its Freepod® nasal spray pump - one of the delivery systems for Haleon's Otrivin® brand - is now made with mass balance bio-based resins. This is the first Aptar delivery system using such materials to be commercialized globally. The use of more sustainable renewable plastic resources is a meaningful measure to help reduce the use of fossil-based materials in healthcare primary packaging. Reinforcing circularity in pharmaceutical packaging Aptar Pharma's Freepod® spray pump used with Haleon's Otrivin® Nasal Spray is made of 52% ISCC Plus certified bio-based feedstock. The bottle is produced using a mass balance approach equivalent to 100% bio-based content. Together, the pump and bottle components result in an overall circular material content of 60% for the full nasal spray device. ISCC PLUS certified manufacturing and supply chain Aptar Pharma is committed to helping its customers meet their sustainability goals, such as reducing the use of fossil-based materials in packaging. The Freepod® nasal spray components are made from bio-based resins derived from renewable feedstocks like bio-waste and residual oils, using an ISCC PLUS-certified mass balance approach. The Aptar Pharma manufacturing site in Mezzovico, Switzerland, is ISCC PLUS certified, ensuring full traceability of materials throughout the manufacturing process and supply chain. ISCC Plus certification also covers all external suppliers - including injection molding providers, service partners, and warehouses - guaranteeing a fully (ISCC) certified supply chain for the Freepod® components. Partnership for a more sustainable approach The joint sustainability approach between Haleon (formerly GSK Consumer Healthcare) and Aptar Pharma is built on a long-term partnership spanning over 30 years. This collaboration has led to significant achievements, including the Otrivin® Freepod® winning the World Packaging Award in 2019 for its innovative and sustainable design. The use of bio-based or renewable feedstocks for the Otrivin® products with Freepod® technology supports Haleon's goal to reduce virgin petroleum-based plastic use by 10% by 2025** and by a third by 2030, compared to 2022 levels. Aptar Pharma's Freepod® for Otrivin®, available globally, demonstrates Aptar's commitment to sustainability and innovation. Looking ahead, this collaboration is anticipated to extend to Otrivin Nasal Mist, Haleon's latest microdroplet technology, which is being rolled out globally since 2023. "At Aptar, sustainability is not just a responsibility - it's a strategic advantage," commented Gael Touya, President of Aptar Pharma. "The launch of Freepod® Futurity™ reflects our commitment to developing solutions that respond to consumers' increasing demand for more sustainable healthcare delivery technologies. As a trusted partner to Haleon, we are proud to help drive the success of the Otrivin® brand while enabling a shift away from fossil-based materials in primary packaging. Supporting our partners in reaching their environmental goals reinforces our vision of supporting the healthcare industry, from Formulation to patient." With a strong commitment to sustainability, Aptar Pharma continuously strives to reduce its environmental impact and support its partners in achieving their sustainability goals. *ISCC Plus certified bio-based feedstock, mass balance approach.**The end point for the goal delivery period is the end of the 2025 calendar year. About Aptar Pharma Aptar Pharma is part of AptarGroup, Inc. (NYSE:ATR), a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar's innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding. View source version on Contacts Media Contact: Ciara JacksonAptar Pharma+49 151 1951

Father-son startup MAUI Imaging raises $14 million to transform ultrasound technology. Read its pitch deck.
Father-son startup MAUI Imaging raises $14 million to transform ultrasound technology. Read its pitch deck.

Business Insider

time23 minutes ago

  • Business Insider

Father-son startup MAUI Imaging raises $14 million to transform ultrasound technology. Read its pitch deck.

Medical startup MAUI Imaging announced Tuesday it has raised $14 million in Series D funding to develop ultrasound technology that can glimpse beyond traditional devices. While ultrasounds are mostly used for soft tissue, MAUI says it's developing a system to see through and around traditional barriers like bone, gas, fat, instruments, and implants. The company aims to expedite diagnosis and treatment, particularly in trauma scenarios, given that this kind of imaging typically requires CT or MRI scans. A father-son duo founded MAUI — an acronym for Multiple Aperture Ultrasound Insonification — out of their Silicon Valley garage in 2006. The late Don Specht started developing the technology while building space telescopes at Lockheed Martin, and sought — alongside his son David, a former Air Force flyer-turned-entrepreneur who serves as MAUI's CEO — to apply it to the human body. "We had to wait for Moore's Law to catch up," David Specht said of MAUI's long developmental road. The company emerged from stealth in August 2024 with a $4 million Department of Defense contract to study its applications in the field. The military is particularly interested in using the portable system for trauma assessment by corpsmen or medics with minimal training, Specht said. "They're trying to move the decision-making point as far forward as possible because they don't have enough doctors," Specht said. He added that MAUI's imaging results in a massive trove of data that could be useful for AI health tools. MAUI counts eight employees and eight consultants, and it has raised roughly $40 million to date. The Series D included equity funding and was led by ultrasound device company Acertara, which now has exclusive distribution rights to the system. The average sales price for the system is $85,000, plus maintenance costs, Specht said. While the FDA has cleared the device for traditional ultrasound uses, MAUI — which has 160 patents — will use data gleaned from its clinical trials with the military as it seeks clearance to make claims about seeing through and around obstructions. Here's a look at the pitch deck MAUI Imaging used to raise its $14 million Series D. Some slides and details have been redacted in order to share the deck publicly. MAUI Imaging MAUI Imaging MAUI Imaging MAUI Imaging MAUI Imaging MAUI Imaging MAUI Imaging MAUI Imaging MAUI Imaging MAUI Imaging MAUI Imaging MAUI Imaging MAUI Imaging MAUI Imaging MAUI Imaging

FDA to announce crackdown on synthetic substance derived from kratom
FDA to announce crackdown on synthetic substance derived from kratom

Washington Post

time23 minutes ago

  • Washington Post

FDA to announce crackdown on synthetic substance derived from kratom

Health officials plan to announce measures Tuesday to crack down on an opioid-like substance found in tablets, gummies and drinkable shots commonly sold in convenience stores. The Department of Health and Human Services said in an advisory that it is targeting potentially dangerous products made of 7-OH, a potent substance synthesized from a compound in the kratom leaf, which grows on trees native to Southeast Asia. The Food and Drug Administration, researchers and kratom companies have grown increasingly alarmed by the rise of 7-OH products they say are distinct from all-natural plant teas and powders.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store